. Author manuscript; available in PMC: 2011 Dec 21.

Published in final edited form as: Expert Opin Investig Drugs. 2010 Sep 16;19(11):1355–1366. doi: 10.1517/13543784.2010.520701

Table 1.

Signal transduction cascades relevant to Akt-mediated cell growth and proliferation.

Drug	Manufacturer	Description
Perifosine	AEterna Zentaris	Phase II trials show activity in hematologic malignancies (Waldenstrom’s macroglobulinemia and multiple myeloma) and solid tumors (RCC, NSCLC, colorectal cancer). Phase III trials underway in metastatic colorectal cancer and multiple myeloma.
MK-2206	Merck & Co	Single agent MTD defined in a phase I study in advanced solid tumors. Ongoing phase I studies are assessing the combination of MK-2206 with cytotoxic therapy, and disease specific studies in HER2-overexpressing breast cancer are assessing MK-2206 with trastuzumab and trastuzumab/lapatinib.
RX-0201	Rexahn	Phase II studies ongoing in RCC and pancreatic cancer.
PBI-05204	Phoenix Biotechnology	Phase I trial in advanced solid tumors ongoing.
GSK2141795	GlaxoSmithKline	Phase I trial in advanced solid tumors ongoing.
Erucylphosphocholine (ErPC)	AEterna Zentaris	In preclinical development.
GSK690693	GlaxoSmithKline	Clinical development suspended.
XL-418	Exelixis	Clinical development suspended.